נורמיטן 50 ישראל - עברית - Ministry of Health

נורמיטן 50

abic ltd. - atenolol - טבליה - atenolol 50 mg - atenolol - atenolol - management of angina pectoris and hypertension, including hypertension of renal origin. late intervention after acute myocardial infarction

טרנדייט טבליות 200 מג ישראל - עברית - Ministry of Health

טרנדייט טבליות 200 מג

padagis israel agencies ltd, israel - labetalol hydrochloride - טבליה - labetalol hydrochloride 200 mg - labetalol - labetalol - treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.

רמיפריל טבע  5 מג ישראל - עברית - Ministry of Health

רמיפריל טבע 5 מג

teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 5 mg - ramipril - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

רמיפריל טבע  5 מג ישראל - עברית - Ministry of Health

רמיפריל טבע 5 מג

teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 5 mg - ramipril - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

אוקסאאר 50 מג ישראל - עברית - Ministry of Health

אוקסאאר 50 מג

organon pharma israel ltd., israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: ocsaar is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to ocsaar is not recommended. renal protection in type-2 diabetic patients with proteinuria: ocsaar is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. ocsaar is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of ocsaar on the primary deposite endpoint was lar

לוסרטה 50 ישראל - עברית - Ministry of Health

לוסרטה 50

cts chemical industries ltd, israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losartan indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to losartan is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losartan on the primary composite end point

ויאגרה 25 מג ישראל - עברית - Ministry of Health

ויאגרה 25 מג

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 25 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

ויאגרה 50 מג ישראל - עברית - Ministry of Health

ויאגרה 50 מג

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 50 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

ויאגרה 100 מג ישראל - עברית - Ministry of Health

ויאגרה 100 מג

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 100 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

מרקאין אדרנלין % 0.5 ישראל - עברית - Ministry of Health

מרקאין אדרנלין % 0.5

tec-o-pharm-libra ltd - bupivacaine hydrochloride 5 mg/ml; epinephrine as tartrate 5.5 mcg/ml - solution for injection - bupivacaine - nerve blocks of long duration where substantial muscle relaxation is not a requirement e.g. in obstetrics, for postoperative pain relief and also therapeutic and diagnostic blocks.